A dental composition is provided as a coating comprising glass flakes providing improved wear-5 resistance and aesthetic properties. The compositions may be used in the treatment of dentine hypersensitivity, dental caries, or in the protection of a tooth from the external environment of the mouth.

A dental composition is provided as a coating comprising glass flakes providing improved wear-5 resistance and aesthetic properties. The compositions may be used in the treatment of dentine hypersensitivity, dental caries, or in the protection of a tooth from the external environment of the mouth.

The present invention relates to PTH prodrugs, pharmaceutical compositions comprising such PTH prodrugs and their uses.

The present invention relates to a platelet lysate foam obtained from blood derivative (allogenic or autologous) which retains the biological properties of the platelet lysate and has optimal properties, in particular mechanical but also storage, which allow sale thereof and make handling thereof easier.

The present invention also relates to the use of a platelet lysate foam for therapeutic purposes, cell culture and cell therapy.

The present invention also relates to a process for getting a platelet lysate foam by a process of drying in a supercritical CO.sub.2 atmosphere.

The present invention relates to a method of reducing or preventing the symptoms associated with the intake of alcohol. The method comprises administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a H.sub.1-antihistamine.

Pharmaceutical compositions and methods of treatment or prevention of diseases and conditions associated with or characterized by at least one of xerostomia and periodontal disease by modulation of the nitric oxide synthase pathway are provided, as are animal models and drug screening methods. Such modulation may be achieved by the administration of tetrahydrobiopterin (BH.sub.4) or its prodrugs and/or salts. Treating and preventing xerostomia can have the downstream effect of also preventing periodontitis, dental caries, parotid gland enlargement, inflammation and fissuring of the lips (chelitis), inflammation or ulcers of the tongue and buccal mucosa, oral candidiasis, salivary gland infection (sialadenitis), halitosis, and cracking and fissuring of oral mucosa.

Pharmaceutical compositions and methods of treatment or prevention of diseases and conditions associated with or characterized by at least one of xerostomia and periodontal disease by modulation of the nitric oxide synthase pathway are provided, as are animal models and drug screening methods. Such modulation may be achieved by the administration of tetrahydrobiopterin (BH.sub.4) or its prodrugs and/or salts. Treating and preventing xerostomia can have the downstream effect of also preventing periodontitis, dental caries, parotid gland enlargement, inflammation and fissuring of the lips (chelitis), inflammation or ulcers of the tongue and buccal mucosa, oral candidiasis, salivary gland infection (sialadenitis), halitosis, and cracking and fissuring of oral mucosa.

A human oral care composition, includes safe and effective amounts of the fluoride ion and stabilized chlorine dioxide, that may take the form of a paste, gel, rinse, spray, powder, varnish or similar that reduces demineralization and promotes remineralization of teeth. The method includes the topical application of the composition to the human oral cavity (including but not limited to the teeth, gingiva, and tongue), preferably at least once daily, to enhance the anti-caries effect of fluoride by released chlorine dioxide compromising any biofilm present.

Described herein is a bifunctional peptide, compositions comprising the same, and methods useful for treatment of peri-implant disease.

The invention provides a method for the production of a zeolite particle composition which has optimized characteristics, such as enhanced adsorption and specific ion exchange properties. A method and an apparatus for producing improved zeolite particle compositions are provided, where the particles are treated with an oxygen-containing gas during micronisation. The zeolite particle compositions can be used in a method for treatment of the human or animal body by therapy and/or prophylaxis, and specifically in a method of treating or preventing conditions of the human or animal body or symptoms of these conditions that are related to heavy metals, endotoxins, exotoxins, and/or bacterial, viral or parasitic intoxications in or of the digestive system, mucosal surfaces or the skin. Also, new zeolite particle compositions can be used as food additive, as filter for purification of water, in packaging materials, or as cosmetic ingredient.